You have not verified your Email yet. Please verify your Email to create alerts
Verify EmailGLENMARK
Glenmark Pharma
|
Gland Pharma
|
Piramal Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
13.0 . | 346.0 . | n/a |
Number of ANDA's Approved By USFDA
|
25.0 . | 279.0 . | n/a |
Domestic Sales Growth - YoY
|
8.4 % | n/a | 15.43 % |
R&D as a % of Total Sales
|
10.61 % | 4.8 % | 0.69 % |
Financials
|
|||
5 yr Average ROE
|
11.3 % | 16.21 % | 5.92 % |
5yr average Equity Multiplier
|
1.97 | 1.1 | 1.98 |
5yr Average Asset Turnover Ratio
|
0.79 | 0.53 | 0.53 |
5yr Avg Net Profit Margin
|
7.09 % | 26.96 % | 5.44 % |
Price to Book
|
2.9 | 3.65 | 2.2 |
P/E
|
0.0 | 46.06 | 0.0 |
5yr Avg Cash Conversion Cycle
|
-113.73 Days | 149.18 Days | 0.0 |
Inventory Days
|
50.29 Days | 119.02 Days | 66.26 Days |
Days Receivable
|
44.33 Days | 100.77 Days | 80.7 Days |
Days Payable
|
209.82 Days | 98.36 Days | 152.43 Days |
5yr Average Interest Coverage Ratio
|
4.6 | 245.99 | 3.64 |
5yr Avg ROCE
|
17.22 % | 21.02 % | 7.05 % |
5yr Avg Operating Profit Margin
|
19.07 % | 38.8 % | 18.65 % |
5 yr average Debt to Equity
|
0.62 | 0.0 | 0.64 |
5yr CAGR Net Profit
|
-20.31 % | 0.21 % | n/a |
5yr Average Return on Assets
|
5.67 % | 14.66 % | 3.14 % |
Shareholdings
|
|||
Promoter Holding
|
46.65 % | 57.86 % | 35.02 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.02 % | -0.5 % | 0.23 % |
Change in Mutual Fund Holding (3 Yrs)
|
5.26 % | 11.61 % | 5.74 % |
Glenmark Pharma
|
Gland Pharma
|
Piramal Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|